|
|
Profile
|
Delegates :
Mr. Tasuku Okamoto |
|
Incorporated :
June 23 , 2023 |
Paid in Capital :
6 Million yen |
Employees :
人 |
Address :
1-101-1 Sakuragi-cho Naka-ku, Yokohama, Kanagawa Cross Gate 7th Floor, KANAGAWA
〒231-0062
|
TEL/FAX :
045-550-5639 / |
URL：
https://opticell.co.jp/english/ |
Attachment :
|
Mission/Background :
Opticell, Ltd. aims to develop cellular medicine. The core technology is called direct cell reprogramming or transdifferentiation, which enables somatic cells such as fibroblasts to differentiate into different organ cells.
By applying this technology to medical treatment, the company hopes to enable personalized cellular medicine to repair tissues damaged by diseases and disorders.
|
|
Technology & Business
|
Our main technology is direct cell reprogramming, or transdifferentiation, in which somatic cells such as fibroblasts are differentiated directly into different organ cells. The new technology allows cells to be directly differentiated from somatic cells, such as fibroblasts, into different organ cells without going through pluripotent stem cells. This new technology does not involve gene transfer into cells, but uses proprietary bioactive peptides and organoid culture technology to generate hematopoietic progenitor cells, neural progenitor cells, etc. from human fibroblasts. We are currently expanding the types of organ cells that can be produced.
We are also creating a neoantigen discovery model by integrating our proprietary peptide and cancer stem cell organoid production technology. We aim to develop applications for T-cell infusion therapy (TIL therapy and TCR-T therapy) in cancer immunotherapy and cancer vaccine therapy using neoantigens.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Transdifferentiation by proprietary peptides
|
Discovery
|
Discovery
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alliance strategy
|
The technology is currently in the domestic transition phase in each country following the filing of a PTC patent application.
We are looking for partners willing to collaborate with us in R&D and academia to establish a scientific POC.
|
|
|